COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Treatment Free Remission After Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Protocol No
HJKC3-0003
Principal Investigator
Ehab Atallah
Phase
II
Summary
The purpose of this study is to determine if adding asciminib to imatinib prior to a second attempt at stopping imatinib will lead to prolonged treatment free remission.
Description
Treatment Free Remission After Asciminib plus Imatinib in CP-CML
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category
Hematologic/Blood Related Cancers
ClinicalTrials.gov
go to website